Catharina Suharti
Department of Internal Medicine, School of Medicine, Diponegoro University and Dr. Kariadi Hospital, Semarang, Indonesia, Jl. Dr. Sutomo 18 Semarang

Published : 7 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Medica Hospitalia

Curcumin for Quality of Life of Multiple Myeloma Patients: a Randomized, Placebo-Controlled Trial: Curcumin for Quality of Life of Multiple Myeloma Patients: a Randomized, Placebo-Controlled Trial Hendrawati, Anindita Rosenda Eka; Santosa, Damai; Dharminto, Dharminto; Suharti, Catharina
Medica Hospitalia : Journal of Clinical Medicine Vol. 9 No. 2 (2022): Med Hosp
Publisher : RSUP Dr. Kariadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (292.578 KB) | DOI: 10.36408/mhjcm.v9i2.757

Abstract

Background : The main goal of multiple myeloma (MM) therapy is to control the disease, prolong the survival, and improve the life quality. Curcumin affects pro-inflammatory cytokines. There is no research yet that has been conducted to evaluate the effects of curcumin on increasing MM patient's life quality. Objective of this study is to evaluate the effect of curcumin on increasing MM patients' life quality. Methods : Of 24 MM patients were enrolled and were divided randomly into treatment groups (n=12) and controls (n=12). Patients in treatment group received melphalan 4 mg/m2, prednisone 40 mg/m2 (MP) for 7 days and curcumin 8 grams/day for 28 days. The control group received MP and placebo. Quality of life (QoL) scores were measured in early diagnosis and after 4 cycles of treatment. The difference between two groups was analyzed using Mann-Whitney U-Test or Independent T Test. Results : The role function score of the treatment group was better than control. There is a significant difference function score of patients between the treatment and control group, at baseline and 4 cycles treatment (41.66 ± 3.85 vs. 23.61 ± 3.36; 95.83 ± 1.03 vs 76.39 ± 2.51; p=0.022). There was significantly different of insomnia score between treatment and control goup at baseline and the end 4 cycles (41.67 ± 3.79 vs 58.33 ± 3.51; 9.72 ± 1.5 vs 25 ± 1.32; p=0.02). Conclusion : The addition of curcumin in myeloma patients enhances the QoL score, role function score and lowered symptom insomnia.
Nilai Rerata Volume Trombosit, Rasio Trombosit Limfosit, Rasio Rerata Volume Trombosit-Limfosit sebagai Prediktor Tingkat Keparahan Sindrom Koroner Kronik Wijaya, Friska; Limantoro, Charles; Fitria, Indah; Suharti, Catharina; Nugroho, Trilaksana
Medica Hospitalia : Journal of Clinical Medicine Vol. 10 No. 1 (2023): Med Hosp
Publisher : RSUP Dr. Kariadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36408/mhjcm.v10i1.813

Abstract

BACKGROUND: The increase in platelet aggregation and inflammation play an essential role in atherosclerosis. Furthermore, the level of activity depends on their size, with larger platelets facilitating the thrombosis process. Severe Coronary Artery Disease (CAD) is associated with low lymphocyte count. It is also linked with Mean platelet volume [MPV], Platelet Lymphocyte Ratio [PLR], and Mean Platelet Volume to Lymphocyte Ratio [MPVLR]. OBJECTIVE:  This study aims to investigate MPV, PLR, and MPVLR as predictors of the severity of Coronary Artery Lesion in Chronic Coronary Syndrome (CCS) using the Gensini score. METHOD: This is a cross sectional study conducted in Dr. Kariadi General Hospital, involving a total sample of 68 respondents. Furthermore, CCS were evaluated before conducting coronary angiography. The study comprises of two group of patients divided according to their Gensini scores, namely mild and severe, for ≤ 20 and > 20, respectively. MPV, PLR, and MPVLR were then compared between the two groups. RESULT: At a cut-off level of 3.4, MPVLR predicted the coronary artery severity with a sensitivity, specificity, positive predictive value (PPV), and negative predictive value of 80%, 50%, 82%, and 47% (area under the curve [AUC] 0.67; 95% confidence interval [CI], 0.52-0.82; p 0.029). Meanwhile, its value ≥3.4 has OR 1.55; 95% CI, 0.99-2.43; p 0.034. CONCLUSION: This study conclude that MPVLR ≥3.4 can be used as a predictor of Coronary Artery Lesion Severity based on the Gensini score in CCS cases.